Conclusion of a non-exclusive rebate agreement for the active substance ofloxacin

Summary

The tender concerns the conclusion of a non-exclusive rebate agreement for medicines containing ofloxacin between DAK-Gesundheit and interested pharmaceutical companies. Under the agreement, bidders may specify their medicines in an annex to the contract. The agreement is due to enter into force on 01/08/2026 and end on 31/07/2028, with an option to extend it once by 12 months. The notice does not set out precise participation or evidence requirements; these must be checked in the tender documents.